Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.63% | -18.20% | -5.55% | 27.16% | -154.25% |
| Total Depreciation and Amortization | -30.86% | -1.47% | -2.81% | 5.71% | 15.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.52% | 215.95% | 111.41% | -9.82% | 127.50% |
| Change in Net Operating Assets | -975.08% | 54.43% | 210.88% | -127.00% | -94.95% |
| Cash from Operations | -1.38% | 24.12% | 23.13% | -13.38% | -15.56% |
| Capital Expenditure | -1,290.70% | 45.86% | 12.39% | 97.68% | 97.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 152.12% | -49.68% | 2.31% | -250.77% | 38.67% |
| Cash from Investing | 146.47% | -49.69% | 2.64% | -260.92% | 85.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 36,369.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 1,838.89% | -- | 2,096.55% | 46,029.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.84% | -121.71% | 70.61% | -1,883.71% | 511.39% |